Abstract #2072
Multiple Sclerosis lesion fingerprint using multicontrast MRI
Guillaume Bonnier 1,2 , Alexis Roche 1,3 , David Romanasco 4 , Samanta Simioni 2 , Djalel-Eddine Meskaldji 4 , David Rotzinger 3 , Ying-Chia Lin 5 , Gloria Menegaz 5 , Myriam Schluep 2 , Renaud Du Pasquier 2 , Tilman Johannes Sumpf 6 , Jens Frahm 6 , Jean-Philippe Thiran 4 , Gunnar Krueger 1,7 , and Cristina Granziera 1,2
1
Advanced Clinical Imaging technology group,
Siemens-CIBM, EPFL, Lausanne, Vaud, Switzerland,
2
Department
of Clinical Neurosciences, Centre Hospitalier
Universitaire Vaudois and University of Lausanne,
Lausanne, Vaud, Switzerland,
3
Department
of Radiology, Centre Hospitalier Universitaire Vaudois
and University of Lausanne, Vaud, Switzerland,
4
STI
/ IEL / LTS5, EPFL, Lausanne, Vaud, Switzerland,
5
Dept.
of Computer Science, University of Verona, Itlay, Italy,
6
Biomedizinische
NMR Forschungs GmbH, Max Planck Institute for
Biophysical Chemistry, Gottingen, Germany, Germany,
7
Healthcare
Sector IM&WS S, Siemens Schweiz AG, Lausanne, Vaud,
Switzerland
Conventional magnetic resonance imaging (MRI) measures
of multiple sclerosis patients provide limited
information about the nature and the extent of brain
damage and repair. We established a clinically
compatible protocol including quantitative MRI
techniques (qMRI, T1, T2, T2* relaxometry) and
semiquantitative Magnetisation Transfer Imaging to
provide a comprehensive MRI fingerprint (CMF) of lesions
that is more adherent to the real underlying pathology
and to assess the CMF contribution to clinical
performances in patients. Lesions characteristics,
revealed by combination of q/sq MRI, highly correlated
with patients clinical performance and more severe
lesions appeared to drive the clinic-radiological
correlations.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
